Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Thoracic 1Plasma cell 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 307Lung Neoplasms 111Adenocarcinoma of Lung 23Non-Squamous Non-Small Cell Lung Cancer 21Neoplasms 21Adenocarcinoma, Bronchiolo-Alveolar 15Brain Neoplasms 14Neoplasm Metastasis 10Squamous Cell Carcinoma of Head and Neck 5Respiratory Tract Diseases 5Carcinoma 5Breast Neoplasms 5Adenocarcinoma 5Thoracic Neoplasms 4Recurrence 4Pancreatic Neoplasms 4NSCLC 4Colorectal Neoplasms 4Colonic Neoplasms 4Salivary Gland Neoplasms 3Respiratory Tract Neoplasms 3Rectal Neoplasms 3Lung Diseases 3Esthesioneuroblastoma, Olfactory 3Carcinoma, Squamous Cell 3Carcinoma, Renal Cell 3Thymoma 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Pleural Effusion, Malignant 2

Interventions

Nivolumab 3trametinib 2pertuzumab 2dabrafenib 2binimetinib 2Trastuzumab 2Azacitidine 2ulixertinib 1trastuzumab biosimilar HLX02 1tazemetostat 1sapanisertib 1romidepsin 1ribociclib 1relatlimab 1palbociclib 1osimertinib 1omipalisib 1margetuximab 1larotrectinib 1itacitinib 1ipatasertib 1erdafitinib 1defactinib 1copanlisib 1cobimetinib 1cc-486 1capivasertib 1bintrafusp alfa protein, human 1adavosertib 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Erlotinib Hydrochloride × Thoracic × Clear all
NCT02355431 2019-03-08

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Incyte Corporation

Phase 2 Withdrawn
Other hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡